

Louis A. Morris, Ph.D.

FTC-NAD Disclosure Workshop

May 22, 2001

Rx Drugs Advertising

- DTC Promotion at \$ 2 billion/year
- \$ 488 million/year on prime/network TV
 - Spending up 26% from last year
 - Category ranks 5th
 - After cars/trucks and restaurants
 - Before credit cards and soft drinks
- Rx Sales rose 15%, to \$145 billion

Broadcast Ad Disclosures

- General Requirement Brief Summary
 - Statement of major risks and side effects
 - Adequate provision for dissemination of prescribing information

Risk Communication

- Major statement
 - Content determined by "Fair Balance"
 - based on product label
 - Integrated into Ad: audio or audio/visual
 - Prominence and readability
 - Size, contrast, distractions

Dissemination Outlets

- Additional Information Available
 - Toll-free telephone number
 - Concurrently running print ad (magazine reference)
 - Web address
 - Ask doctor (HCP) for information

Graded Disclosures

- Fair Balance
 - Overall presentation of risks and benefits
 - Sufficient contextual Information
 - Supers can augment but not make make misleading information nonmisleading
- Dissemination Outlets
 - Notification sufficient (can use supers)



